Radiometals are used in targeted tumour radiotherapy and developing generators and cyclotrons to produce positron-emitting radiometals. These radiopharmaceuticals contain a bifunctional chelator to hold the radiometal attached to a vector molecule.
Technetium-99m is the most frequently used diagnostic radionuclide in SPECT imaging and requires coordination in diverse chemical chelates. The radiometals used for therapeutic applications include copper-67 and yttrium-90. However, for diagnostic imaging, the following radiometals include copper-61, copper-62, copper-64, zirconium-89 and gallium-68.
The demand for radiopharmaceuticals labelled with radiometals is due to a theranostic approach. These radiometals combine imaging and therapy in the same radiopharmaceutical. For example, the theranostic match pairs diagnostic and therapy: gallium-68/lutetium-177, gallium-68/yttrium-90, copper-64/copper-67, yttrium-86/yttrium-90 are amongst other radiometals are used in targeted radiotherapy.
In certain cases, a single radionuclide can be theranostic, as in the case of copper-64 (both β+ and β- decays) and terbium-149 (both β+ and α decays). Copper-64 provides a low-energy positron comparable to fluorine-18, and it decays, emitting both β+ and β- particles with an acceptable long half-life of 12.7 hours.
Over the past decade, positron emission tomography imaging (PET imaging) agents labelled with gallium-68 have undergone a significant increase in clinical applications. Gallium-68 is produced from the germanium-68/gallium-68 generator.
However, gallium-68-labelled radiopharmaceuticals are more cost-effective than cyclotron-produced PET radioisotopes. The most prominent radiopharmaceuticals currently used for imaging and differentiating several neuroendocrine tumours include 68Ga-DOTATOC, 68Ga-DOTATATE, and 68Ga-DOTANOC. In addition, gallium-68 has a convenient half-life of 68 minutes and provides sufficient radioactivity for various PET imaging applications by delivering acceptable radiation dosages to the patients.
You are here:
home »
Astatine-211 Sodium Astatide, evolving thyroid treatment, enters trials, promising enhanced precision and safety over traditional Iodine-131 NaI therapy.
Astatine-211 Sodium Astatide: The Next Generation in Thyroid Disease Treatment Read Post »
Therapeutic nuclear medicine leverages radionuclides for targeted cancer treatment, facing challenges in delivery, safety, and regulatory compliance.
225Ac-Lintuzumab, targeting CD33, shows promise in AML treatment with potential expansion to other cancers.
Actinium-225 Lintuzumab: A Breakthrough in Acute Myeloid Leukaemia Treatment Read Post »
225Ac-FPI-2068 and 111In-FPI-2107 represent a major advancement in targeted alpha therapy for various solid tumours.
Imaging agents can be used to evaluate organ function, detect cancer, measure blood flow and follow metabolic processes.
Radiometals for diagnostic imaging and theranostics Read Post »
Overview on the central role of chelation in labelling radiocompounds.
Basic premises to molecular imaging and radionuclide therapy Read Post »
